Glenmark Pharmaceuticals (GLENMARK) Fundamentals 2026 — P/E 45.6x, Revenue Analysis | SniperIQ
Glenmark Pharmaceuticals (GLENMARK) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹62,039 Crore, trading at ₹2198.20 on the BSE. This SniperIQ fundamentals page covers Glenmark Pharmaceuticals's valuation (P/E 45.6x, P/B 5.9x), profitability (net margin 8.0%), revenue (₹16,983 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Glenmark Pharmaceuticals's market cap?
Glenmark Pharmaceuticals (GLENMARK) has a market capitalization of approximately ₹62,039 Crore, trading at ₹2198.20 on the BSE. Market cap moves with the live share price.
What is Glenmark Pharmaceuticals's P/E ratio?
Glenmark Pharmaceuticals's trailing twelve-month P/E ratio is 45.6x, with a price-to-book (P/B) of 5.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals runs a net profit margin of 8.0%, a gross margin of 47.6%, and an operating margin of 20.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Glenmark Pharmaceuticals generate?
Glenmark Pharmaceuticals reported revenue of ₹16,983 Crore for fiscal year 2026, with net income of ₹1,362 Crore and earnings per share (EPS) of 48.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Glenmark Pharmaceuticals pay a dividend?
Glenmark Pharmaceuticals offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Glenmark Pharmaceuticals financially healthy?
Glenmark Pharmaceuticals carries a debt-to-equity ratio of 0.06x and a current ratio of 1.77x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Glenmark Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Glenmark Pharmaceuticals (GLENMARK) the key facts are: market cap ₹62,039 Crore, P/E 45.6x, revenue ₹16,983 Crore, 52-week range 1794-2471.05. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Glenmark Pharmaceuticals's full fundamentals live
Get Glenmark Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.